Phil’s knowledge and experience will help us move Advanced Circulatory’s products to the next level.
(PRWEB) July 24, 2012
Advanced Circulatory Systems, Inc., (http://www.advancedcirculatory.com) makers of multiple medical devices providing perfusion therapy to the first responder and hospital marketplace, has named Philip W. Faris Executive Advisor and Member at Large of the Board of Directors. In these roles, Faris will provide experienced leadership and guidance as the company secures investment to stage focused growth initiatives and move the company’s products into standard practices of medicine.
Faris has a distinguished track record of building market-leading companies in emerging medical markets and has successfully performed as CEO for over three decades in start-up, early stage, and high-growth organizations. He is currently CEO and managing partner at ProSavant International, a strategic consulting firm for the medical device and biotechnology space. He also serves as Executive Chairman of the Board at Innovative Trauma Care (an early-stage medical device company developing and marketing point of injury solutions), on the Executive Committee of BioMed SA (a non-profit organization promoting the bioscience industry in San Antonio, Texas), and as a Board Member and Senior Advisor for Vivo Biosciences (an Alabama-based biotechnology company). Through his career, Faris has acted as CEO and Director at Vidacare Corporation, VidiMedix Corporation, Trestle Corporation, Diatek Corporation and many other medical device, biotechnology and health care companies.
“Phil’s knowledge and experience will help us move Advanced Circulatory’s products to the next level,” commented President Mike Black. “We are thrilled to be working with him.”
Advanced Circulatory has developed a novel platform therapy called Perfusion on Demand™- a therapy that has life saving implications for multiple emergency medical conditions. Perfusion on Demand is a non-invasive therapy that increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised. This gives rescuers and caregivers the potential to return people to a full life after severe medical emergencies, including sudden cardiac arrest, hemorrhagic shock and traumatic brain injury. The company’s current focus is in the sudden cardiac arrest market, which is an estimated $700 million market for Perfusion on Demand products. The company estimates the global market opportunity for Perfusion on Demand products to be $3.3 billion. Advanced Circulatory currently manufactures and markets the ResQPOD® (Perfusion on Demand) and the ResQGARD™ Impedance Threshold Devices.
About Advanced Circulatory Systems, Inc.
Advanced Circulatory Systems, Inc. is a privately held manufacturer of advanced circulatory technology based in Roseville, Minnesota (http://www.advancedcirculatory.com). Its mission is to restore life and improve the quality of life for patients experiencing cardiac arrest, low blood pressure and head injury by developing new technologies to non-invasively increase circulation throughout the body, improving opportunities for survival and quality of life. The company manufactures and markets the ResQPOD, a version of which is currently available for sale and in use at more than 1,200 hospitals and EMS systems throughout the US, and the CardioPump, which is currently available for sale only outside the US. More information on the company is available at http://www.advancedcirculatory.com. For company interviews or images, please contact ctsang(at)henryschafer(dot)com.